Blog

SDNY comments on EMVR's application in pharma context

Authors

On December 3, 2013, Judge Cote of the Southern District of New York issued a lengthy bench trial order in Astrazeneca AB v. Apotex Corp., 01 Civ. 9351 (DLC) (Doc. No. 240), addressing a number of damages issues. The only issue we address here involves the entire market value rule. In particular, the court commented on its applicability in pharma cases. It also cited language from Uniloc in which the Federal Circuit suggested that entire market value rule could be satisfied if the patented feature substantially created the value of the component parts. We quote in full because the language is interesting (slip op. at 82-84):

pd1pd2pd3pd4pd6

The opinions expressed are those of the authors on the date noted above and do not necessarily reflect the views of Fish & Richardson P.C., any other of its lawyers, its clients, or any of its or their respective affiliates. This post is for general information purposes only and is not intended to be and should not be taken as legal advice. No attorney-client relationship is formed.